According to our total peptide library, we have constructed an advanced High-throughput screening (HTS) peptide drug screening platform, using this platform to provide customers with peptide drug design and management automation services.
High-throughput screening (HTS) technology is based on experimental methods at the molecular and cellular levels, using microplates as the experimental tool carrier, performing the test process with an automated operating system, collecting experimental result data with sensitive and rapid detection equipment, and analyzing it by computer processing experimental data, detecting tens of millions of samples at the same time, and using the corresponding database to support the operation of the technical system, it has the characteristics of trace, fast, sensitive and accurate.
According to the peptide sequence information provided by Creative Peptides total peptide library, we have constructed an advanced HTS peptide drug screening platform, which uses a microtiter plate to screen in 96, 384 and 1536 well plates in miniature format. Through a reasonable and effective HTS process, using strict quality control metrics to identify poor data, and the standardized mean difference (SSMD) is used to evaluate the data quality in HTS analysis to improve hit screening. According to customer needs, Creative Peptides can provide low-cost new drug screening services. Specifically, we provide customers with peptide drug design and management automation services.
HTS is a method for rapidly testing a large number of peptide samples using automated systems and sensitive detection tools. It allows for the efficient screening of peptide drug candidates by testing tens of millions of samples simultaneously, accelerating the drug discovery process.
Our HTS platform offers high hit screening rates, quick results, and low-cost mass screening. With precise data analysis and strict quality control metrics, it ensures accurate identification of potential peptide drugs with no interference or cross-contamination.
We utilize 96, 384, and 1536-well microtiter plates for peptide drug screening. The process is automated, and data is collected using rapid detection equipment. We apply SSMD (Standardized Mean Difference) to evaluate data quality, ensuring reliable hit identification.
We ensure that all peptide samples undergo thorough purification, with quality control data provided for each peptide, including RP-HPLC and MS results. We also take steps to prevent cross-contamination by freeze-drying peptides in individual tubes or orifices.
Yes, our HTS platform screens peptides for their binding affinity to specific targets, ensuring high specificity and accuracy in identifying potential drug candidates.
The turnaround time for HTS screening is fast, enabling efficient and large-scale screening of peptides, thus accelerating the early stages of peptide drug development.
References
